U.S. Markets closed
  • S&P 500

    3,750.77
    -98.85 (-2.57%)
     
  • Dow 30

    30,303.17
    -633.87 (-2.05%)
     
  • Nasdaq

    13,270.60
    -355.47 (-2.61%)
     
  • Russell 2000

    2,108.70
    -41.16 (-1.91%)
     
  • Crude Oil

    52.59
    -0.02 (-0.04%)
     
  • Gold

    1,840.20
    -10.70 (-0.58%)
     
  • Silver

    25.24
    -0.30 (-1.17%)
     
  • EUR/USD

    1.2114
    -0.0031 (-0.2544%)
     
  • 10-Yr Bond

    1.0140
    -0.0260 (-2.50%)
     
  • Vix

    32.64
    +9.62 (+41.79%)
     
  • GBP/USD

    1.3686
    +0.0010 (+0.0725%)
     
  • USD/JPY

    104.1010
    +0.3450 (+0.3325%)
     
  • BTC-USD

    31,310.23
    -1,051.53 (-3.25%)
     
  • CMC Crypto 200

    628.91
    -11.01 (-1.72%)
     
  • FTSE 100

    6,567.37
    -86.64 (-1.30%)
     
  • Nikkei 225

    28,635.21
    +89.01 (+0.31%)
     

Alexion (ALXN) in Focus: Stock Moves 7.9% Higher

Zacks Equity Research
·2 min read

Alexion Pharmaceuticals, Inc. ALXN was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $105.36 to $116.57 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Alexionhas a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Alexion Pharmaceuticals, Inc. Price

Alexion Pharmaceuticals, Inc. Price
Alexion Pharmaceuticals, Inc. Price

Alexion Pharmaceuticals, Inc. price | Alexion Pharmaceuticals, Inc. Quote

Investors interested in the Medical – Biomedical and Genetics industry may consider Emergent Biosolutions Inc EBS which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research